Med2Date — Clinical Guidelines
Home Geriatric Medicine Parkinson's Disease Dementia

Parkinson's Disease Dementia

Last updated 1 Jun 2026 · Geriatric medicine

📋 Key Information Summary

📋
  • Parkinson's disease dementia (PDD) develops in the context of established idiopathic Parkinson's disease (PD), typically ≥1 year after motor symptom onset; this temporal relationship is the key distinguishing feature from dementia with Lewy bodies (DLB).
  • Prevalence of dementia in PD ranges from 25–80% depending on disease duration and age, with an estimated 4-fold increased risk compared with age-matched controls.
  • The cognitive profile of PDD is characterised by prominent executive dysfunction (planning, set-shifting, working memory), with relative preservation of early episodic memory compared with Alzheimer's disease.
  • Visual hallucinations, fluctuating attention and alertness, and REM sleep behaviour disorder are core features that overlap significantly with DLB.
  • The 1-year rule distinguishes PDD from DLB: if cognitive symptoms begin ≥1 year after the onset of cardinal parkinsonian motor features, the diagnosis is PDD; if dementia occurs within 1 year of motor onset (or before), the diagnosis is DLB.
  • A thorough medication review is essential — anticholinergics, dopamine agonists, levodopa doses, benzodiazepines and opioids may all contribute to or worsen cognitive impairment and hallucinations.
  • Rivastigmine (Exelon®) is the only cholinesterase inhibitor with TGA-approved indication and PBS authority listing for PDD in Australia; it improves cognition and neuropsychiatric symptoms with an NNT of approximately 10.
  • For PDD-associated psychosis, quetiapine at low doses (12.5–50 mg nocte) is first-line; clozapine is effective but requires blood monitoring; pimavanserin is not yet PBS-listed in Australia.
  • Driving capacity must be formally assessed in all PDD patients; cognitive impairment and visual hallucinations are contraindications to driving per Austroads guidelines.
  • Caregiver burden in PDD exceeds that of PD alone; structured caregiver education, respite care and early referral to Parkinson's specialist nurses and Dementia Support Australia (1800 699 799) are recommended.
  • Aboriginal and Torres Strait Islander Australians experience higher rates of earlier PD onset and barriers to specialist access; culturally safe dementia care pathways and community-based support are essential.
  • Advance care planning should be initiated early after PDD diagnosis, while the person retains decision-making capacity, and documented in the My Health Record or state-based advance directive system.

Introduction & Australian Epidemiology

Parkinson's disease dementia (PDD) is a progressive neurocognitive disorder that develops in the setting of established idiopathic Parkinson's disease. It represents a major milestone in the disease trajectory, profoundly affecting prognosis, medication management, caregiver burden, safety planning and quality of life. PDD is classified as a Lewy body dementia along with dementia with Lewy bodies (DLB), sharing a common underlying neuropathology of cortical α-synuclein deposition, but differing in the temporal relationship between motor and cognitive symptom onset.

In Australia, Parkinson's disease affects approximately 150,000–200,000 people, with incidence increasing with age and higher prevalence in males. The Australian Institute of Health and Welfare (AIHW) estimates that 30–40% of people with PD will develop dementia over the course of their illness, with rates rising to 60–80% in long-term follow-up studies exceeding 10 years. Dementia is the single strongest predictor of mortality in PD, increasing the hazard ratio for death by 2–3-fold and commonly precipitating admission to residential aged care facilities (RACFs).

The economic burden of PDD in Australia is substantial, encompassing direct healthcare costs, PBS-subsidised medications, residential care and the often-unrecognised costs of informal caregiving. The National Aboriginal and Torres Strait Islander Health Survey and AIHW data indicate that neurological conditions, including PD, are under-recognised in Indigenous populations, contributing to delayed diagnosis and management.

⚠️
Prognostic significance: Development of dementia in PD reduces median survival to approximately 5–7 years from dementia onset and significantly accelerates functional decline, falls risk, and institutionalisation. Early recognition and proactive management are therefore critical.

This guideline addresses the clinical approach to PDD in the Australian healthcare context, focusing on diagnostic distinction from DLB, cognitive profiling, pharmacological management including cholinesterase inhibitors, and the essential domains of safety, capacity assessment and caregiver support.

Diagnostic Distinction from Dementia with Lewy Bodies

PDD and DLB share overlapping clinical features and a common Lewy body neuropathological substrate. The critical differentiating factor is the temporal sequence of symptom onset. Both conditions are diagnosed according to the revised consensus criteria published by McKeith et al. (2017) and the Movement Disorder Society (MDS) Task Force criteria for PDD (Emre et al., 2007; Dubois et al., 2007).

The 1-Year Rule

The consensus operationalised "1-year rule" provides the boundary between DLB and PDD:

🚨
Diagnostic criterion: If dementia develops before or within 1 year of the onset of cardinal parkinsonian motor features (resting tremor, rigidity, bradykinesia), the diagnosis is DLB. If dementia develops ≥1 year after the onset of clinically diagnosed idiopathic PD, the diagnosis is PDD.

MDS Diagnostic Criteria for Probable PDD

  • Core features: Diagnosis of PD according to MDS clinical criteria, with PD motor features preceding cognitive decline by ≥1 year.
  • Cognitive features: Impairment in ≥2 cognitive domains (attention, executive, visuospatial, memory); deficit severe enough to impair daily functioning (not solely explained by motor impairment).
  • Supportive features: Prominent executive dysfunction, impaired free recall with cueing benefit, visuospatial deficits disproportionate to AD-type amnesia, cognitive fluctuations, excessive daytime somnolence, visual hallucinations, paranoid ideation, REM sleep behaviour disorder.
  • Exclusion features: Cerebrovascular disease sufficient to account for cognitive impairment, other concurrent neurological or medical conditions, depression as sole cause of cognitive impairment.
Feature PDD DLB AD (comparison)
Motor–cognitive interval ≥1 year after motor onset Dementia ≤1 year of motor onset or before Motor features absent or late
Cardinal parkinsonism Yes (by definition) May be subtle or absent early Not typical
Visual hallucinations Common (50–75%) Core feature (present in ≥80%) Less common (early stages)
Cognitive fluctuations Common Core feature Rare early
RBD Very common (often predates dementia) Very common (probative feature) Uncommon
Memory profile Executive retrieval deficit; cueing benefit Similar to PDD Encoding/storage deficit; poor cueing benefit
Response to levodopa Motor response typically present Variable or poor motor response Not applicable
CT/MRI brain Non-specific atrophy; no vascular burden Similar to PDD Medial temporal atrophy prominent
DaTSCAN Abnormal (reduced uptake) Abnormal (reduced uptake) Normal

Diagnostic Investigations

Essential Cognitive screening: MoCA or MMSE MoCA is preferred in PDD due to greater sensitivity for executive dysfunction (cut-off <26/30). MMSE may underestimate deficits. Both are freely available to Australian clinicians.
Essential Detailed neuropsychological assessment Formal neuropsych battery assessing attention, executive function (Trail Making, Stroop), visuospatial (pentagon copying, clock drawing), memory (RAVLT with encoding/recall/cueing distinction) and language. Available through public hospital neurology/geriatrics services and private neuropsychologists (Medicare rebatable under GP Mental Health Treatment Plan allied health items where applicable).
Available Blood investigations (exclude reversible causes) FBC, UEC, LFTs, TFTs, vitamin B12, folate, calcium, glucose, HIV serology (if indicated), syphilis serology. MBS items 65060/65070 (general pathology).
Available CT or MRI brain MRI preferred (excluding stroke, subdural, hydrocephalus, structural lesions). MBS item 63024 (MRI brain). May be reported as "non-specific cerebral atrophy" in PDD.
Referral DaTSCAN (Ioflupane-123 SPECT) Available at select nuclear medicine centres (e.g., Royal Melbourne, RPA, Royal Brisbane). MBS item 61412 (DAT imaging). Useful when diagnostic uncertainty exists between PDD/DLB and non-synucleinopathy dementia (e.g., AD). Not routinely required if parkinsonism is clinically definite.
Referral PET amyloid imaging (PiB or florbetapir) Available at limited specialist centres. Not PBS-subsidised (out-of-pocket ~,000–3,000). May help exclude comorbid AD pathology in atypical presentations.
Specialist CSF biomarkers (Aβ42, total tau, p-tau, α-synuclein seed amplification assay) Available at specialist centres (e.g., academic hospitals). CSF α-synuclein SAA (real-time quaking-induced conversion, RT-QuIC) has high sensitivity/specificity for Lewy body pathology. Currently research-only in most Australian centres.

Cognitive Profile and Hallucinations

The cognitive profile of PDD is distinct from that of Alzheimer's disease and carries important implications for assessment, management and prognostication. Understanding the pattern of deficits guides both pharmacological and non-pharmacological intervention.

Cognitive Domains Affected in PDD

Prominent
Executive Dysfunction
Impaired planning, mental flexibility (set-shifting), dual-task processing, working memory, and abstract reasoning. Often the earliest and most disabling cognitive deficit. Manifests as difficulty managing medications, finances and complex instrumental activities of daily living (IADLs).
Key tests: Trail Making B, Stroop, Wisconsin Card Sorting, verbal fluency (letter and category)
Prominent
Visuospatial Dysfunction
Impaired spatial orientation, depth perception, face recognition, and constructional ability. Contributes to falls, driving difficulties, and visual hallucinations. Out of proportion to the degree of memory impairment.
Key tests: Pentagon copying (MMSE), clock drawing, Rey Complex Figure, facial recognition test
Variable
Memory Impairment
Retrieval-based pattern with relative preservation of encoding and storage. Free recall is impaired but recognition and cueing typically improve performance, distinguishing PDD from the encoding/storage deficit of Alzheimer's disease. Episodic memory does decline progressively.
Key tests: RAVLT (Rey Auditory Verbal Learning Test), delayed recall with recognition, logical memory

Fluctuating Cognition and Attention

Cognitive fluctuations are a hallmark of Lewy body dementias and occur in approximately 50–70% of PDD patients. They manifest as episodic periods of reduced alertness, staring, excessive somnolence, or incoherent speech alternating with periods of relative lucidity. Fluctuations may be mistaken for seizures, delirium, or medication side effects. Their presence should prompt a search for precipitants including polypharmacy, infection, metabolic disturbance and sleep disorders.

Visual Hallucinations

Visual hallucinations occur in 50–75% of PDD patients over the course of illness and are typically well-formed, complex, and recurrent. Common themes include unfamiliar people in the house, children, small animals, or deceased relatives. The hallucinations are often initially insight-preserving (the patient recognises them as unreal) but may lose insight over time.

⚠️
Medication-related hallucinations: Visual hallucinations in PD/PDD may be iatrogenic — dopamine agonists (pramipexole, ropinirole, rotigotine), anticholinergics (benztropine, trihexyphenidyl), amantadine and high-dose levodopa can all trigger or exacerbate hallucinations. Always perform a medication review before attributing hallucinations to disease progression.

Other Neuropsychiatric Features

  • Depression: Present in 30–50% of PDD; overlaps with apathy and anhedonia. Screen with GDS-15 (Geriatric Depression Scale) rather than PHQ-9, which has insufficient validation in PD.
  • Apathy: Distinguished from depression by absence of sadness and hopelessness; common and debilitating; poor response to SSRIs.
  • Delusions: Typically paranoid (spousal infidelity, theft, persecutory ideas); less common than hallucinations but more distressing and associated with caregiver burnout.
  • REM sleep behaviour disorder (RBD): Dream-enacting behaviour with loss of REM atonia; highly prevalent in PDD (>70%); may predate dementia by years. Assess with bed-partner interview and consider polysomnography (MBS item 12203).
  • Anxiety and panic: May relate to wearing-off phenomena and autonomic dysfunction; can mimic hallucination-related agitation.

Phenotyping Approach

The cognitive and psychiatric phenotype of PDD can be broadly classified into a "cortical" pattern (more prominent cognitive deficits, hallucinations, fluctuations — resembling DLB) and a "subcortical" pattern (more prominent executive deficits, apathy, depression — less frequent hallucinations). This distinction may have prognostic and therapeutic implications and is being studied in the Australian Parkinson's longitudinal cohorts.

Medication Review and Cholinesterase Inhibitors

Medication management in PDD requires careful balancing of motor symptoms, cognitive function, psychiatric features and safety. A structured medication review is the essential first step, followed by targeted pharmacotherapy for cognition and neuropsychiatric symptoms.

Step 1: Medication Review — Minimise Cognitive Harm

Conduct a comprehensive review of all prescribed, over-the-counter and complementary medications. The anticholinergic burden (ACB) should be quantified using the Anticholinergic Cognitive Burden (ACB) Scale.

🚨
Anticholinergic burden: High anticholinergic burden (ACB score ≥3) is independently associated with accelerated cognitive decline in PD. Medications with high ACB scores should be deprescribed where clinically feasible. Avoid or minimise anticholinergic agents including oxybutynin, chlorpheniramine, amitriptyline, benztropine and trihexyphenidyl.
Medication Class Effect on Cognition Action in PDD
Anticholinergics (benztropine, trihexyphenidyl, oxybutynin, chlorpheniramine) Impair attention, memory, executive function Deprescribe — substitute with non-anticholinergic alternatives
Dopamine agonists (pramipexole, ropinirole, rotigotine) Impulse control disorders, hallucinations, confusion, somnolence Taper and withdraw; increase levodopa if motor symptoms worsen
Amantadine Hallucinations, confusion, livedo reticularis Consider withdrawal in PDD with hallucinations
Benzodiazepines (diazepam, temazepam, clonazepam) Sedation, anterograde amnesia, falls Gradual taper; avoid abrupt cessation; use melatonin for sleep
Antipsychotics (risperidone, olanzapine) Extrapyramidal worsening, sedation, cognitive dulling Contraindicated in PDD — switch to quetiapine or clozapine
Opioids (tramadol, oxycodone) Confusion, hallucinations, constipation (worsens PD) Minimise use; prefer paracetamol, duloxetine for pain
SSRIs/SNRIs Generally cognitive-neutral or beneficial for mood Continue if treating depression; avoid paroxetine (high ACB)

Step 2: Optimise Levodopa

Levodopa/carbidopa remains the most effective motor therapy and is relatively cognitive-neutral compared with dopamine agonists. In PDD, the strategy should shift towards levodopa monotherapy at the lowest effective dose. Formulations include immediate-release (Madopar®, Sinemet®) and controlled-release (Madopar HBS®, Sinemet CR®), with Duodopa® (intestinal gel infusion) reserved for advanced PD under specialist supervision.

Step 3: Cholinesterase Inhibitors for Cognitive Impairment

Cholinesterase inhibitors (ChEIs) are the mainstay of pharmacological treatment for PDD. The cholinergic deficit in PDD is profound — loss of nucleus basalis of Meynert neurons is more severe and occurs earlier in the disease course than in Alzheimer's disease.

💊
Rivastigmine
Exelon® · Rivastigmine Sandoz · Acetylcholinesterase/butyrylcholinesterase inhibitor
Adult dose Start 1.5 mg PO BD with food; titrate to 3 mg BD after ≥4 weeks, then to 4.5 mg BD and maximum 6 mg BD as tolerated. Transdermal patch: start 4.6 mg/24 h, titrate to 9.5 mg/24 h then 13.3 mg/24 h.
Paediatric dose Not indicated (PDD is an adult condition)
Route Oral (capsule/solution) or transdermal patch
Duration Ongoing — reassess at 3 months for clinical benefit; continue if stable or improved
Renal adjustment No dose adjustment required; use with caution in severe impairment (eGFR <15)
Hepatic adjustment Reduce dose or use with caution in moderate–severe hepatic impairment (Child-Pugh B/C)
Key adverse effects Nausea, vomiting, diarrhoea, anorexia, weight loss (all more common than donepezil); bradycardia; falls. Transdermal patch has better GI tolerability than oral.
PBS status ✔ PBS Authority Required — for dementia associated with idiopathic Parkinson's disease (Rivastigmine is the only ChEI with TGA-registered indication for PDD in Australia)
💊
Donepezil
Aricept® · Acetylcholinesterase inhibitor
Adult dose Start 5 mg PO nocte; increase to 10 mg nocte after ≥4 weeks
Paediatric dose Not indicated
Route Oral (tablet, orally disintegrating tablet)
Duration Ongoing — reassess at 3–6 months
Renal adjustment No dose adjustment required
Hepatic adjustment Not recommended in severe hepatic impairment
Key adverse effects Nausea, diarrhoea, vivid dreams, bradycardia, syncope (ensure no concurrent β-blocker without monitoring)
PBS status PBS Authority Required — listed for Alzheimer's disease; use in PDD is off-label but supported by evidence and commonly prescribed by Australian neurologists/geriatricians
💊
Galantamine
Reminyl® · Acetylcholinesterase inhibitor with nicotinic modulation
Adult dose Start 4 mg PO BD (or 8 mg MR nocte); titrate to 8 mg BD (16 mg MR) after 4 weeks, then to 12 mg BD (24 mg MR) after a further 4 weeks
Route Oral (tablet, capsule, modified-release capsule)
Renal adjustment Max 16 mg/day if eGFR 9–59 mL/min; avoid if eGFR <9
Hepatic adjustment Not recommended if Child-Pugh ≥7
PBS status PBS Authority Required — listed for Alzheimer's disease; limited evidence in PDD; use only when rivastigmine and donepezil are not tolerated
ℹ️
Rivastigmine in PDD — the evidence: The EXPRESS trial (Emre et al., NEJM 2004) demonstrated significant improvement in ADAS-cog scores (mean difference 2.1 points) and clinician-rated global function in PDD patients treated with rivastigmine versus placebo. Benefits were observed in cognition, activities of daily living, neuropsychiatric symptoms (especially hallucinations) and caregiver burden. The transdermal patch formulation provides comparable efficacy with improved GI tolerability.

Step 4: Management of Psychosis in PDD

PDD-associated psychosis requires a stepwise approach: (1) address reversible causes (infection, metabolic, medications); (2) reduce polypharmacy; (3) commence cholinesterase inhibitor if not already prescribed; (4) consider low-dose antipsychotic if non-pharmacological strategies fail.

💊
Quetiapine
Seroquel® · Atypical antipsychotic
Adult dose Start 12.5 mg PO nocte; titrate by 12.5–25 mg every 3–7 days to target 25–75 mg nocte (rarely up to 100–150 mg). Avoid exceeding 150 mg/day in PDD.
Key adverse effects Somnolence, postural hypotension, falls, QTc prolongation (monitor ECG at baseline), metabolic effects (less than olanzapine)
PBS status ✔ PBS General Benefit
💊
Clozapine
Clozaril® · Atypical antipsychotic (dibenzodiazepine)
Adult dose Start 6.25–12.5 mg PO nocte; titrate by 6.25–12.5 mg increments weekly. Target 25–50 mg/day (doses much lower than schizophrenia dosing). Maximum 100 mg/day rarely needed.
Key adverse effects Agranulocytosis (risk 0.8%) — mandatory FBC monitoring via Clozapine Patient Monitoring Service (CPMS). Sedation, sialorrhoea, constipation, metabolic syndrome, myocarditis (early weeks). Requires certified prescriber registration.
PBS status ✔ PBS Authority Required — authority for treatment-resistant psychosis; may require specialist authority in some states
🚨
Avoid in PDD: First-generation (typical) antipsychotics such as haloperidol are absolutely contraindicated in PDD due to severe extrapyramidal sensitivity with potentially life-threatening parkinsonian crisis, neuroleptic malignant syndrome and increased mortality. Risperidone and olanzapine carry high EPS risk and should also be avoided. Aripiprazole has insufficient evidence and mixed EPS profile in PDD.

Step 5: Memantine

Memantine (Namenda®, Ebixa®) has modest evidence of benefit in PDD for global clinical status and behavioural symptoms. It may be considered as adjunctive therapy when ChEIs are insufficient or not tolerated. Dose: start 5 mg PO daily, titrate by 5 mg weekly to 10 mg BD. Renal adjustment: 5 mg BD if eGFR 5–29 mL/min. PBS Authority Required for moderate–severe Alzheimer's disease; use in PDD is off-label.

Evaluating Treatment Response

Assess response to cholinesterase inhibitor therapy at 3 months using:

  • Clinician global impression (CGI-I) — change from baseline
  • Repeat MoCA or formal neuropsych testing (if baseline available)
  • Caregiver report of neuropsychiatric symptoms (NPI-Q or NPI)
  • ADCS-CGIC or equivalent functional assessment
  • If no discernible benefit after 3 months at adequate dose, consider trial of an alternative ChEI or discontinuation

Safety, Capacity and Caregiver Support

PDD introduces a range of safety risks and ethical considerations that extend beyond cognitive management. Falls, driving, wandering, medication errors and abuse vulnerability require proactive assessment. Decision-making capacity and advance care planning must be addressed early and revisited regularly.

Falls Prevention

PDD patients have a substantially elevated falls risk due to the combination of postural instability (axial PD features), orthostatic hypotension, visuospatial impairment, cognitive fluctuations and polypharmacy. The annual falls rate in PDD exceeds 60%.

  • Multidisciplinary falls risk assessment: physiotherapy (gait, balance, Timed Up and Go), occupational therapy (home safety assessment, MBS item 10958 for OT home visits), podiatry and continence management.
  • Review and minimise medications contributing to orthostasis (dopamine agonists, antihypertensives, diuretics) and sedation (benzodiazepines, quetiapine at higher doses).
  • Consider hip protectors, personal emergency alarm systems and home modifications (grab rails, lighting, remove trip hazards).
  • Vitamin D supplementation (1,000 IU daily) is recommended for all PDD patients with reduced mobility and falls risk, per Australian and New Zealand Society for Geriatric Medicine (ANZSGM) guidelines.

Driving Assessment

🚨
Driving in PDD: Under Austroads Assessing Fitness to Drive (2022) guidelines, a diagnosis of dementia (including PDD) requires formal assessment of cognitive function relevant to driving. Minimum standard: MoCA ≥22/30 or equivalent neuropsychological testing. Visual hallucinations, cognitive fluctuations, excessive daytime somnolence and significant visuospatial impairment are all contraindications to driving. The clinician has a legal and ethical obligation to counsel the patient and, if safety is not assured, to notify the relevant state/territory driver licensing authority (mandatory in most jurisdictions when the patient continues to drive against medical advice). Document all discussions in the clinical record.

Medication Safety

  • Simplify medication regimen — reduce dosing frequency, use blister packs (Webster-pak) or medication management aids (Dose Administration Aids).
  • Involve community pharmacist for Home Medicines Review (MBS item 900) at least annually (or when medication changes occur). HMR is MBS-rebatable and funded by the Australian Government.
  • Assess capacity to self-administer medications; consider supervised administration by community nursing or carer if deficits are significant.
  • Lock away high-risk medications if wandering, confusion or overdose risk is present.

Falls, Wandering and Home Safety

  • Wandering and exit-seeking behaviour: door alarms, GPS tracking devices (e.g., Endeavour Foundation tracking devices; state-based dementia wandering services).
  • Kitchen and bathroom safety: automatic stove shut-off devices, temperature-limited hot water, non-slip mats.
  • Register with the national Safe Return Home program (Alzheimer's Australia / Dementia Australia) for wandering events.

Decision-Making Capacity and Advance Care Planning

Capacity is decision-specific, time-specific and may fluctuate in PDD. It should be assessed for each significant decision (financial, medical, accommodation, driving) using a structured approach consistent with the Australian common law test (understand, retain, weigh, communicate) and relevant state legislation (e.g., Guardianship Act 1987 NSW, Powers of Attorney Act 1998 Vic).

  • Assess and document capacity early after PDD diagnosis, while the person can still participate meaningfully in advance care planning.
  • Facilitate completion of an Advance Care Directive (ACD) — state-specific forms are available (e.g., NSW: Advance Care Planning forms via NSW Health; Vic: Advance Care Planning framework).
  • Appoint an enduring guardian (health and personal decisions) and enduring power of attorney (financial and legal decisions) as soon as practical.
  • Link advance care plans with My Health Record for national accessibility.
  • For patients who have already lost capacity, consider application to the relevant state Civil and Administrative Tribunal (e.g., NCAT NSW, VCAT Victoria, QCAT Queensland) for guardianship or administration orders.

Risk of Abuse and Neglect

People with PDD are at increased risk of financial abuse, neglect, emotional abuse and, less commonly, physical abuse — perpetrated by family members, carers or others. Clinicians should be vigilant for indicators such as unexplained weight loss, medication non-adherence, poor hygiene, social isolation, financial irregularities and caregiver hostility. Report concerns to the relevant state/territory Adult Safeguarding Unit or elder abuse hotline (e.g., NSW Elder Abuse Helpline: 1800 628 221; Qld: 1300 651 192; Vic: Seniors Rights Victoria 1300 368 821).

Caregiver Burden and Support

Caregiver burden in PDD is among the highest of any dementia subtype. The combination of motor dependency, cognitive decline, psychiatric symptoms (especially hallucinations, agitation, delusions), sleep disturbance (RBD, nocturnal confusion) and personality changes places extraordinary strain on spousal and family carers.

1
Early Education
Provide structured education on PDD trajectory, symptom management, communication strategies and when to seek help. Refer to Parkinson's Australia (parkinsons.org.au) and state-based Parkinson's nurse specialists.
2
Respite Services
Access Commonwealth Home Support Programme (CHSP) respite, Carer Gateway (1800 422 737) or My Aged Care (1800 200 422) for respite care, both in-home and residential. Carer Gateway provides free counselling, coaching, online skills courses and emergency respite.
3
Dementia-Specific Support
Dementia Australia (1800 100 500) provides counselling, support groups, education programs and the Dementia Helpline. Dementia Support Australia (DSA, 1800 699 799) provides specialist behaviour support for people with dementia-related behaviours of concern.
4
Carer Mental Health
Screen carers for depression and anxiety (PHQ-9, GAD-7). Carer-specific psychological support is available via GP Mental Health Treatment Plan (up to 20 sessions/year). Consider referral to carer support groups through Parkinson's NSW/Vic/Qld/SA/WA.
5
Residential Care Transition
When home-based care is no longer sufficient, facilitate a planned transition to residential aged care with dementia-specific capability. Ensure medication management continuity, Parkinson's specialist nurse review and advance care plan transfer. Apply for Aged Care Assessment Team (ACAT/RAS) assessment via My Aged Care.

Multidisciplinary Team Approach

Optimal PDD management requires a coordinated multidisciplinary team including: general practitioner (care coordination, medication management), neurologist or geriatrician (diagnosis, complex medication management), neuropsychologist (cognitive assessment), Parkinson's disease nurse specialist, physiotherapist, occupational therapist, speech pathologist (swallowing and communication), social worker, community pharmacist, and palliative care (when appropriate). In regional and remote areas, telehealth consultations via the MBS telehealth items (e.g., items 91790, 91800) are essential for maintaining specialist access.

Aboriginal and Torres Strait Islander Health Considerations
Prevalence and data gaps
Parkinson's disease and associated dementia in Aboriginal and Torres Strait Islander Australians are under-recognised and under-reported. AIHW data suggests neurodegenerative conditions are increasing in First Nations populations, compounded by earlier onset of comorbidities (diabetes, cardiovascular disease) that may accelerate neurodegeneration. The Australian Institute of Health and Welfare's Dementia in Aboriginal and Torres Strait Islander peoples report highlights significant data gaps and the need for culturally appropriate prevalence studies.
Diagnostic barriers
Cognitive screening tools (MoCA, MMSE) were not developed or validated for Aboriginal and Torres Strait Islander populations and may not adequately account for cultural and linguistic diversity, educational background, or concepts of time and spatial orientation. The Kimberley Indigenous Cognitive Assessment (KICA) is a culturally validated screening tool designed for use with Aboriginal Australians in northern Australia. Consider using KICA-cog for screening and refer for neuropsychological assessment with a culturally competent clinician where available.
Access to specialist services
Aboriginal and Torres Strait Islander people, particularly those in remote and very remote communities (46% of First Nations Australians reside outside major cities, per ABS Census), face significant barriers to neurology and geriatrics services. Parkinson's nurse specialists are concentrated in metropolitan areas. Telehealth (MBS items for video consultation) and visiting specialist services (e.g., RFDS, Indigenous health outreach programs) are critical for closing this gap. Aboriginal Community Controlled Health Organisations (ACCHOs) play a central role in chronic disease and dementia care coordination.
Cultural concepts of dementia and ageing
Dementia may be understood differently in Aboriginal and Torres Strait Islander communities — terms like "getting old in the head" or "muddled up" may be used rather than medicalised language. Cognitive decline in Elders may be accepted as part of ageing rather than viewed as a treatable condition. Health promotion should be delivered in culturally safe, community-led settings, using yarning-based approaches and visual resources developed for First Nations audiences. Dementia Australia offers culturally specific resources.
Medication access and adherence
PBS medications including rivastigmine are available through ACCHOs and Remote Area Aboriginal Health Services, often with Closing the Gap co-payment support (PBS co-payment reduced to .70 per script for eligible patients holding a concession card and registered with a CTG-eligible condition). However, supply chain disruptions, pharmacy access in remote communities and low health literacy can impact adherence. Medication management reviews (HMR/RMMR) should be offered proactively. Transdermal rivastigmine patch may be preferred where oral adherence is unreliable.
Carer and family support
In Aboriginal and Torres Strait Islander communities, caring responsibilities are often shared among extended family networks (kinship systems). However, this places collective strain on families, particularly where multiple generations are affected by chronic disease and disability. Carer Gateway (1800 422 737) and Dementia Australia (1800 100 500) provide services; however, engagement may require outreach through local Aboriginal health workers and liaison officers. Respite services may be geographically inaccessible in remote areas.
Advance care planning and sorry business
Advance care planning should be approached with cultural sensitivity. Conversations about future care, end of life and death must respect cultural protocols around naming of deceased persons, sorry business and the role of Elders. The Australian Government's National Framework for Advance Care Planning and the Respecting Patient Choices program include guidance for culturally appropriate advance care planning with First Nations peoples. Where capacity is lost, culturally appropriate guardianship and decision-making processes should involve family and community Elders.

📚 References

  1. 1. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Movement Disorders. 2007;22(12):1689–1707.
  2. 2. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100.
  3. 3. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. New England Journal of Medicine. 2004;351(24):2509–2518.
  4. 4. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the Movement Disorder Society Task Force. Movement Disorders. 2007;22(16):2314–2324.
  5. 5. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Movement Disorders. 2005;20(10):1255–1263.
  6. 6. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database of Systematic Reviews. 2012;(3):CD006504.
  7. 7. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670–1683.
  8. 8. Australian Institute of Health and Welfare (AIHW). Dementia in Australia. Cat. no. DEM 2. Canberra: AIHW; 2023.
  9. 9. Austroads. Assessing Fitness to Drive. 4th ed. Sydney: Austroads; 2022.
  10. 10. Smith KJ, Peterson KA, O'Connell JC, et al. Risk of dementia in Parkinson's disease: a population-based cohort study. Brain. 2022;145(9):3186–3197.
  11. 11. LoGiudice D, Smith K, Thomas J, et al. Kimberley Indigenous Cognitive Assessment tool (KICA): development of a cognitive assessment tool for older Indigenous Australians. International Psychogeriatrics. 2006;18(2):269–280.
  12. 12. Dementia Australia. Dementia and Aboriginal and Torres Strait Islander peoples. Fact sheet. Melbourne: Dementia Australia; 2022.
  13. 13. Fleisher JE, Sajatovic M, Hammer JL, et al. Engagement in mental health treatment among veterans with Parkinson's disease and comorbid psychiatric disorders. Movement Disorders Clinical Practice. 2021;8(5):728–736.
  14. 14. Royal Australian College of General Practitioners (RACGP). Management of Parkinson's disease in general practice — A guide for the healthcare team. Melbourne: RACGP; 2020.
  15. 15. National Health and Medical Research Council (NHMRC). National Statement on Ethical Conduct in Human Research. Canberra: NHMRC; 2023 (updated). Relevant to capacity assessment frameworks in research and clinical contexts.
for PBS scripts. Utilise ACCHS pharmacies and Remote Area Aboriginal Health Worker programs for medication supply in remote areas. Avoid initiating benzodiazepines; support holistic pain management including community-based exercise programs.
Preventive health
Promote bone health: encourage vitamin D supplementation (1000 IU daily in deficient individuals), smoking cessation support, reduction of alcohol intake, and weight-bearing exercise. MBS Item 715 health checks provide a structured opportunity to assess bone health, screen for osteoporosis risk factors, and discuss musculoskeletal health in a culturally safe context.

Quick Reference: Differential Diagnosis at a Glance

Costovertebral dysfunction
Paracetamol ± NSAID; manual therapy
2–6 weeks
Provocable on palpation; no red flags
Thoracic compression fracture
Paracetamol; ± calcitonin; DXA + osteoporosis Rx
6–12 weeks healing
Elderly; osteoporosis; acute onset
ACS (posterior MI)
Aspirin 300 mg, GTN, heparin; urgent PCI
Time-critical
ECG, troponin; CV risk factors
Aortic dissection
IV labetalol; urgent CT aortogram; surgery (Type A)
Time-critical
Tearing pain; BP differential >20 mmHg
Vertebral osteomyelitis
IV antibiotics (vancomycin + ceftriaxone initially); ID consult
6 weeks IV antibiotics
Fever, elevated CRP, IV drug use
Biliary colic / cholecystitis
Paracetamol ± morphine; lap cholecystectomy
Surgical within 72 h (cholecystitis)
RUQ/infrascapular; post-prandial; RUQ US

📚 References

  1. 1. Briggs AM, Smith AJ, Straker LM, Bragge P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. BMC Musculoskelet Disord. 2009;10:77.
  2. 2. National Health and Medical Research Council (NHMRC). Evidence-based management of acute musculoskeletal pain. Canberra: NHMRC; 2003 (updated 2020).
  3. 3. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
  4. 4. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268(6):760–765.
  5. 5. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Europ Spine J. 2018;27(1):60–75.
  6. 6. Erwin WM, Jackson PC, Homonko DA. Innervation of the human costovertebral joint: implications for clinical back pain syndromes. J Manipulative Physiol Ther. 2000;23(6):395–403.
  7. 7. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th edn. Melbourne: RACGP; 2018 (updated 2023).
  8. 8. Hirsch JA, Singh V, Falco FJE, et al. Thoracic facet joint interventions. Pain Physician. 2016;19(4):E581–E593.
  9. 9. Erwin WM, Jackson PC. The costovertebral joint: anatomy, biomechanics, and clinical significance in thoracic back pain syndromes. J Can Chiropr Assoc. 2003;47(2):112–120.
  10. 10. Strayer RJ, Gunnerson JM, Brown LH, et al. Aortic dissection: clinical features, diagnosis, and management. Aust Crit Care. 2019;32(2):144–153.
  11. 11. Ombregt L. A system of orthopaedic medicine. 3rd edn. Edinburgh: Churchill Livingstone Elsevier; 2013. Chapter 18: Thoracic spine.
  12. 12. Lin CC, Chen KH, Li DM, et al. Characteristics and outcomes of patients presenting with thoracic back pain to the emergency department. Emerg Med Australas. 2020;32(5):805–811.
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).